Von Willebrand factor - LFB

Drug Profile

Von Willebrand factor - LFB

Alternative Names: vWF SD-35-DH; Wilfactin; Willefact; Willfact

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LFB
  • Developer AOP Orphan Pharmaceuticals AG; LFB
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Proteins; Recombinant proteins
  • Mechanism of Action Von Willebrand factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 17 Apr 2015 The product is approved in Estonia, Hungary, Latvia, Lithuania, Sweden, Slovakia and Slovenia for Von Willebrand's disease
  • 11 Oct 2013 No development reported - Phase-II for Von Willebrand's disease in USA (Parenteral)
  • 03 Apr 2013 Launched for Von Willebrand's disease in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top